Financial Highlights and Outlook [Second Quarter 2024 Financial Highlights](index=1&type=section&id=Second%20Quarter%202024%20Financial%20Highlights) Aveanna's Q2 2024 revenue grew 7.0% to $505.0M, with Adjusted EBITDA up 27.3% to $45.6M, though net income declined Q2 2024 Key Financial Metrics | Metric | Q2 2024 | Change vs. Q2 2023 | | :--- | :--- | :--- | | Revenue | $505.0 million | +7.0% | | Gross Margin | $158.3 million | +1.9% | | Net Income | $13.9 million | -45.7% | | Adjusted Net Income | $2.5 million | +$6.6 million | | Adjusted EBITDA | $45.6 million | +27.3% | [Management Commentary](index=1&type=section&id=Management%20Commentary) Management attributes strong Q2 results to strategic transformation, driven by payor partnerships, caregiver investments, and cost reductions - CEO Jeff Shaner highlighted that the **7.0% revenue** and **27.3% Adjusted EBITDA growth** confirm the success of the company's strategic transformation and its focus on being a value-based homecare provider[2](index=2&type=chunk) - CFO Matt Buckhalter emphasized leveraging growth through strategic cost reductions, lower overhead, and successes in the preferred payor strategy and Government Affairs rate improvements[8](index=8&type=chunk) [Revised Full Year 2024 Guidance](index=3&type=section&id=Revised%20Full%20Year%202024%20Guidance) Aveanna raised full-year 2024 guidance, projecting revenue over $1,985M and Adjusted EBITDA exceeding $158M after strong Q2 Updated Full Year 2024 Guidance | Metric | New Guidance | Prior Guidance | | :--- | :--- | :--- | | Revenue | > $1,985 million | > $1,970 million | | Adjusted EBITDA | > $158 million | > $150 million | - The company is not providing guidance on net income due to the volatility of certain inputs, such as fair value adjustments for interest rate swaps and caps[9](index=9&type=chunk) Detailed Financial Results [Consolidated Results of Operations](index=1&type=section&id=Consolidated%20Results%20of%20Operations) H1 2024 revenue grew 6.1% to $995.6M, shifting from a net loss to $2.7M net income, with Adjusted EBITDA up 25.2% to $80.5M [Three-Month Period Ended June 29, 2024](index=1&type=section&id=Three-Month%20Period%20Ended%20June%2029%2C%202024) Q2 2024 revenue rose 7.0% to $505.0M, driven by PDS and MS segments, though gross margin percentage declined and net income fell to $13.9M Q2 2024 vs Q2 2023 Consolidated Results | Metric | Q2 2024 | Q2 2023 | Change | | :--- | :--- | :--- | :--- | | Revenue | $505.0M | $471.9M | +7.0% | | Gross Margin | $158.3M | $155.3M | +1.9% | | Net Income | $13.9M | $25.6M | -45.7% | | Diluted EPS | $0.07 | $0.13 | -46.2% | | Adjusted EBITDA | $45.6M | $35.9M | +27.3% | [Six-Month Period Ended June 29, 2024](index=3&type=section&id=Six-Month%20Period%20Ended%20June%2029%2C%202024) H1 2024 revenue grew 6.1% to $995.6M, led by PDS and MS, achieving $2.7M net income from a prior loss, with Adjusted EBITDA up 25.2% H1 2024 vs H1 2023 Consolidated Results | Metric | H1 2024 | H1 2023 | Change | | :--- | :--- | :--- | :--- | | Revenue | $995.6M | $938.4M | +6.1% | | Gross Margin | $304.1M | $299.7M | +1.5% | | Net Income (Loss) | $2.7M | ($6.4M) | N/A | | Diluted EPS | $0.01 | ($0.03) | N/A | | Adjusted EBITDA | $80.5M | $64.3M | +25.2% | [Segment Performance](index=1&type=section&id=Segment%20Performance) PDS was the primary growth driver in Q2 and H1 2024, with MS also strong, while HHH saw slight revenue decline but significant gross margin improvement [Q2 2024 Segment Performance](index=1&type=section&id=Q2%202024%20Segment%20Performance) Q2 2024 PDS revenue grew 8.0% to $407.9M, MS revenue increased 9.3% to $42.5M, and HHH revenue declined 1.4% but improved gross margin Q2 2024 Revenue by Segment (vs Q2 2023) | Segment | Q2 2024 Revenue | YoY Change | | :--- | :--- | :--- | | Private Duty Services (PDS) | $407.9M | +8.0% | | Home Health & Hospice (HHH) | $54.6M | -1.4% | | Medical Solutions (MS) | $42.5M | +9.3% | [H1 2024 Segment Performance](index=3&type=section&id=H1%202024%20Segment%20Performance) H1 2024 PDS revenue grew 7.0% to $802.9M, MS revenue increased 9.6% to $83.5M, and HHH revenue declined 2.1% but expanded gross margin H1 2024 Revenue by Segment (vs H1 2023) | Segment | H1 2024 Revenue | YoY Change | | :--- | :--- | :--- | | Private Duty Services (PDS) | $802.9M | +7.0% | | Home Health & Hospice (HHH) | $109.2M | -2.1% | | Medical Solutions (MS) | $83.5M | +9.6% | Liquidity and Capital Resources [Liquidity, Cash Flow, and Debt](index=3&type=section&id=Liquidity%2C%20Cash%20Flow%2C%20and%20Debt) As of June 29, 2024, Aveanna had $47.7M cash, $1,480.2M total debt, and $221.2M in available liquidity, with H1 2024 free cash flow at $(12.4)M - As of June 29, 2024, the company had total liquidity of approximately **$268.9 million**, comprising **$47.7M cash**, **$53.0M securitization facility capacity**, and **$168.2M revolver capacity**[7](index=7&type=chunk) Indebtedness as of June 29, 2024 | Instrument | Amount (in thousands) | | :--- | :--- | | 2021 Extended Term Loan | $895,150 | | Second Lien Term Loan | $415,000 | | Securitization Facility | $170,000 | | **Total Indebtedness** | **$1,480,150** | Cash Flow Summary (Six Months Ended June 29, 2024) | Cash Flow Item | Amount (in thousands) | | :--- | :--- | | Net cash used in operating activities | $(10,163) | | Net cash used in investing activities | $(2,577) | | Net cash provided by financing activities | $16,459 | | **Free Cash Flow** | **$(12,363)** | - The company utilizes interest rate swaps and caps to hedge its interest rate exposure on a significant portion of its variable rate debt[7](index=7&type=chunk) Non-GAAP Financial Measures [Definitions and Reconciliations](index=4&type=section&id=Definitions%20and%20Reconciliations) The company utilizes non-GAAP measures like Adjusted EBITDA and Free Cash Flow to assess performance, providing detailed reconciliations for these adjusted metrics - **Adjusted EBITDA** is a key metric used by management, defined as EBITDA adjusted for items such as goodwill impairments, share-based compensation, acquisition costs, and restructuring costs[11](index=11&type=chunk) - **Field Contribution** is a non-GAAP measure defined as gross margin less branch and regional administrative expenses, used to assess the performance of core field operations[14](index=14&type=chunk) Reconciliation of Net Income to Adjusted EBITDA (Q2 2024) | (in thousands) | Q2 2024 | | :--- | :--- | | Net Income | $13,906 | | Interest, Taxes, D&A | $32,424 | | **EBITDA** | **$46,330** | | Adjustments | $(683) | | **Adjusted EBITDA** | **$45,647** | Reconciliation of Net Income to Adjusted Net Income (Q2 2024) | (in thousands) | Q2 2024 | | :--- | :--- | | Net Income | $13,906 | | Adjustments (pre-tax) | $(10,610) | | Tax Impact of Adjustments | $(824) | | **Adjusted Net Income** | **$2,472** |

Core Viewpoint - Wall Street analysts expect Aveanna Healthcare to report a quarterly loss of $0.02 per share, indicating no change from the previous year, with revenues projected at $494.02 million, reflecting a 4.7% increase year-over-year [1] Group 1: Earnings Estimates - The consensus EPS estimate for the upcoming quarter has remained unchanged over the past 30 days, indicating analysts' reassessment of their projections [1] - Changes in earnings estimates are crucial for predicting investor reactions to the stock [1] Group 2: Revenue Projections - Analysts predict 'Revenue- PDS' will reach $396.11 million, representing a 4.9% increase from the year-ago quarter [2] - The estimate for 'Revenue- MS' is projected at $40.88 million, indicating a 5.2% increase year-over-year [2] - 'Revenue- HHH' is estimated at $55.25 million, suggesting a slight decline of 0.3% compared to the prior-year quarter [2] Group 3: Stock Performance - Aveanna's shares have returned +46.6% over the past month, contrasting with a -5.9% change in the Zacks S&P 500 composite [3] - Aveanna holds a Zacks Rank 3 (Hold), indicating expected performance in line with the overall market [3]

ATLANTA, July 18, 2024 (GLOBE NEWSWIRE) -- Aveanna Healthcare Holdings Inc. ("Aveanna") (NASDAQ:AVAH) today announced that the company will release its second quarter results before the market open on Thursday, August 8, 2024, to be followed by a conference call at 10:00 a.m. (Eastern Time) on the same day. The conference call can be accessed live over the phone by dialing 1-877-407-0789 or for international callers, 1-201-689-8562. A replay will be available two hours after the call and can be accessed by ...

ATLANTA, July 18, 2024 (GLOBE NEWSWIRE) -- Aveanna Healthcare Holdings Inc. (“Aveanna”) (NASDAQ: AVAH) today announced that the company will release its second quarter results before the market open on Thursday, August 8, 2024, to be followed by a conference call at 10:00 a.m. (Eastern Time) on the same day. The conference call can be accessed live over the phone by dialing 1-877-407-0789 or for international callers, 1-201-689-8562. A replay will be available two hours after the call and can be accessed by ...

Group 1 - Ikena Oncology, Inc. (IKNA) has a Zacks Rank 1 with a 18.7% increase in the Zacks Consensus Estimate for its current year earnings over the last 60 days [1] - Ikena Oncology's shares increased by 28.9% in the last three months, outperforming the S&P 500's 10.4% gain [1] - Aveanna Healthcare Holdings Inc. (AVAH) also holds a Zacks Rank 1, with a 22.2% rise in the Zacks Consensus Estimate for its current year earnings over the last 60 days [1] Group 2 - Aveanna Healthcare Holdings' shares rose by 27.1% over the last three months, compared to the S&P 500's 10.3% increase [1] - Velocity Financial, Inc. (VEL) has a Zacks Rank 1, with an 8.3% increase in the Zacks Consensus Estimate for its current year earnings over the last 60 days [2] - Velocity Financial's shares gained 15.1% in the last three months, also outperforming the S&P 500's 10.3% advance [2]

The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Has Aveanna Healthcare (AVAH) been one of those stocks this year? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.Aveanna Healthcare is a member of our Medical group, which includes 1025 different companies and currently sits at #5 in the Zacks Sector Rank. The Zacks Sector Rank includes 16 ...

ATLANTA, May 20, 2024 (GLOBE NEWSWIRE) -- Aveanna Healthcare Holdings Inc. ("Aveanna") (NASDAQ:AVAH) today announced that its management team will attend the UBS Healthcare Services Cape Cod Summit in Chatham, MA on Tuesday, June 4, 2024, and the Jefferies Global Healthcare Conference in New York on Wednesday, June 5, 2024. Management will host 1x1 investor meetings at the UBS Healthcare Services Summit on June 4, 2024. For the Jefferies Global Healthcare Conference on June 5, 2024, management will host 1x1 ...

Aveanna Healthcare Holdings Inc. (NASDAQ:AVAH) Q1 2024 Earnings Conference Call May 9, 2024 10:00 AM ET Company Participants Debbie Stewart - CAO Jeff Shaner - CEO Matt Buckhalter - CFO Conference Call Participants Ben Hendrix - RBC Capital Markets Scott Fidel - Stephens Pito Chickering - Deutsche Bank Brian Tanquilut - Jefferies Operator Good morning, and welcome to Aveanna Healthcare Holdings' First Quarter 2024 Earnings Conference Call. Today's call is being recorded, and we have allocated one hour for p ...

Financial Performance - Aveanna Healthcare reported a quarterly loss of $0.03 per share, better than the Zacks Consensus Estimate of a loss of $0.05, and an improvement from a loss of $0.05 per share a year ago [1] - The company achieved a revenue of $490.65 million for the quarter ended March 2024, exceeding the Zacks Consensus Estimate by 1.16% and up from $466.41 million year-over-year [1] Earnings Surprises - The quarterly report represents an earnings surprise of 40%, and Aveanna has surpassed consensus EPS estimates three times over the last four quarters [1] - A quarter ago, the company was expected to post a loss of $0.02 per share but actually reported a loss of $0.01, delivering a surprise of 50% [1] Stock Performance and Outlook - Aveanna shares have declined approximately 9.7% since the beginning of the year, contrasting with the S&P 500's gain of 8.8% [2] - The current consensus EPS estimate for the upcoming quarter is -$0.03 on revenues of $491.17 million, and for the current fiscal year, it is -$0.09 on revenues of $1.98 billion [4] Industry Context - The Medical - Outpatient and Home Healthcare industry, to which Aveanna belongs, is currently ranked in the top 32% of over 250 Zacks industries, indicating a favorable outlook compared to the bottom 50% [5] - The performance of Aveanna's stock may be influenced by the overall industry outlook, as the top 50% of Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1 [5]

Financial Performance - First Quarter Revenue was $490.7 million, a 5.2% increase over the prior year [1][2] - Gross margin increased 1.0% to $145.9 million, compared to Q1 2023 [3] - First Quarter Net loss was $11.2 million, compared to net loss of $32.0 million in the comparable prior year period [3] - Adjusted EBITDA was $34.9 million, a 22.5% increase compared to the prior year quarter [4] Segment Performance - Revenue from Private Duty Services (PDS) segment increased by $22.1 million, while Medical Solutions (MS) segment revenue increased by $3.7 million [2] - Home Health & Hospice (HHH) segment revenue decreased by $1.5 million over the comparable quarter [2] Guidance and Outlook - Full Year 2024 Revenue guidance raised to greater than $1,970 million [1][8] - Full Year 2024 Adjusted EBITDA guidance raised to greater than $150 million [1][8] Liquidity and Cash Flow - As of March 30, 2024, the company had cash of $42.6 million and incremental borrowing capacity of $10.0 million under its securitization facility [5] - Free cash flow was $(12.7) million for 2024 [5] Management Commentary - CEO Jeff Shaner highlighted the positive momentum at Aveanna, emphasizing the growth in revenue and Adjusted EBITDA [2] - CFO Matt Buckhalter expressed pride in the revenue growth and the expectation of operating cash flow positivity for 2024 [7]